Expanded Partnership Includes Medidata Patient Cloud ePRO to
Seamlessly Collect Patient-Centric Data and Automate Manual Processes
for Oncology Research
NEW YORK--(BUSINESS WIRE)--
(NASDAQ:MDSO), the leading global provider of cloud-based technology and
data analytics for clinical research, today announced that BeiGene,
Ltd., a clinical-stage biopharmaceutical company developing innovative
molecularly targeted and immuno-oncology drugs for the treatment of
cancer, will expand its use of the Medidata
Clinical Cloud® to further digitize patient reporting for its
oncology research studies.
BeiGene will leverage Medidata's integrated platform to feed eSource
Patient Reported Outcome data from Medidata's
Patient Cloud ePRO directly into Medidata
Rave®. This infusion of patient recorded outcome data will enable
improved operational efficiency, reduced transcription errors and
reconciliation issues, and decreased data quality risk plans.
"Our expanded partnership with Medidata will establish a technology
platform for our clinical research, which we expect will enable us to
more efficiently execute clinical trials of our portfolio compounds,"
said Ross Pettit, Senior Vice President of Global Development Operations
at BeiGene. "Over the past two years, Medidata has proven to be a key
technology partner for BeiGene, with its industry-leading solutions and
hands-on approach to our integration needs. By automating paper-based
procedures and centralizing patient data on the Medidata platform, we're
able to collaborate globally on our oncology research."
As part of its expanded partnership with Medidata, BeiGene also plans to
standardize the collection and management of safety cases through Medidata
Safety Gateway®, a secure, configurable electronic transmission
interface between EDC and safety systems. The partnership between
BeiGene and Medidata also includes Medidata
Coder®, a cloud application that is designed to streamline and
centralize medical coding to perform oncology research studies.
"Medidata is proud to be accelerating technology advancement at every
level and interaction within the life sciences industry," said Kara
Dennis, Managing Director of Mobile Health at Medidata. "We've created
an environment that is agile, globally collaborative, and in line with
the digital and mobile needs of biotechnology and pharmaceutical
companies, all from one unified cloud platform. BeiGene's
forward-thinking technology approach will enable faster study builds and
centralized control over patient data, facilitating the evaluation of
its portfolio compounds."
is reinventing global drug and medical device development by creating
the industry's leading cloud-based solutions for clinical research.
Through our advanced applications and intelligent data analytics,
Medidata helps advance the scientific goals of life sciences customers
worldwide, including over 850 global pharmaceutical companies, biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make more
informed decisions earlier and faster. Our unparalleled clinical trial
data assets provide deep insights that pave the way for future growth.
The Medidata Clinical Cloud is the primary technology solution powering
clinical trials for 18 of the world's top 25 global pharmaceutical
companies and is used by 18 of the top 25 medical device developers—from
study design and planning through execution, management and reporting.
BeiGene is a global, clinical-stage, research-based biotechnology
company focused on molecularly targeted and immuno-oncology cancer
therapeutics. With a team of over 400 employees in China, the United
States, and Australia, BeiGene is advancing a pipeline consisting of
novel oral small molecules and monoclonal antibodies for the treatment
of cancer. BeiGene is working to create combination solutions aimed at
having both a meaningful and lasting impact on cancer patients.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170724006244/en/
Anthony D'Amico, +1
Snider, +1 646-362-2997
News Provided by Acquire Media